Responses to tamoxifen were significantly prolonged by reducing levels of the enzyme APOBEC3B in preclinical models of estrogen receptor-positive breast cancer and significantly shortened by increasing levels of APOBEC3B, ...
Dec 10, 2015
0
1
A large study of patients with breast cancer who took the anti-cancer drug tamoxifen while taking an antidepressant were not found to have an increased risk of recurrence. The Kaiser Permanente study was published today in ...
Dec 1, 2015
0
4
Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling ...
Oct 13, 2015
0
215
For reasons unknown, many patients with breast cancer treated with the estrogen receptor-blocking drug tamoxifen eventually become resistant to the treatment despite the fact that their cancer cells still have the estrogen ...
Sep 23, 2015
0
17
Concerns about fertility kept a third of young women with breast cancer from taking tamoxifen, despite its known benefit in reducing the risk of breast cancer coming back.
Aug 24, 2015
0
59
Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), ...
Jun 1, 2015
0
29
A number of research studies have shown that coffee helps to protect against breast cancer. A new study led by Lund University, has confirmed that coffee inhibits the growth of tumours and reduces the risk of recurrence in ...
Apr 21, 2015
0
187
Tamoxifen is a prodrug widely used in the treatment of breast cancer, but the patient response to it depends on their ability to metabolize it into endoxifen. Researchers have developed a new method that allows, through a ...
Mar 25, 2015
0
12
Among premenopausal women with early-stage, hormone receptor-positive breast cancer, adding ovarian suppression to tamoxifen reduced breast cancer recurrence for those who had previously received chemotherapy and remained ...
Dec 12, 2014
0
0
The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals.
Dec 11, 2014
0
0
